TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11230488
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose interferon alfa-2b (IFNalpha2b) and GMK
Study: 9021810
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen during induction therapy
Study: 7950332
Drug: Norfloxacin (0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (0.3% solution, 50 ul)
Study: 7950332
Drug: Ofloxacin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (same dose as norfloxacin)
Study: 3296435
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiation and hormonotherapy (17-hydroxyprogesterone caproate)
Study: 28738794
Drug: Pharmacotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy combined with psychoeducation
Study: 23453611
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone as submucosal injection
Study: 19117731
Drug: Teicoplanin (10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (10mg/kg single dose upon introduction of anaesthesia)
Study: 19117731
Drug: Comparator (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (multiple doses of broad-spectrum antimicrobials for 4-6 days)
Study: 16645021
Drug: Lipid-heparin emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-heparin emulsion (LHE) infusion
Study: 17381494
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NaCl 0.9%) infusion (control)
Study: 11394552
Drug: Major and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major and minor stress assessment using Life Experiences Survey and Weekly Stress Inventory
Study: 9932220
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (amoxicillin‐clavulanic acid, 1.5 g/24 h for 10 days)
Study: 8563533
Drug: Mixed therapy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed therapy (deep breathing exercises for low risk patients and incentive spirometry plus physiotherapy for high risk patients)
Study: 1546725
Drug: Trimipramine 25
Normalized name: trimipramine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine 25 mg
Study: 28921781
Drug: VGCV for
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGCV for 100 days followed by 3 doses of monthly CMV HIG
Study: 25817172
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) injection
Study: 25817172
Drug: Focal/grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal/grid laser treatment
Study: 18289149
Drug: Continuous paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paroxetine treatment (20 mg daily)
Study: 18289149
Drug: Intermittent paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent paroxetine treatment (20 mg daily)
Study: 17044464
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide 5-mononitrate (ISMN) 20 mg bid for 5 days
Study: 7918123
Drug: Sequential treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment: three courses of neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. d 1) and 5‐fluorouracil (1000 mg/m2/days 1‐5 by continuous i.v. infusion every 3 weeks) followed by conventional radiotherapy of 65‐70 Gy.
Study: 7918123
Drug: Simultaneous treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment: cisplatin (100 mg/m2 on days 1, 22, 43) given simultaneously with conventional radiotherapy of 65‐70 Gy.
Study: 29855294
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment
Study: 2460431
Drug: Cockroach antigen
Normalized name: American cockroach allergenic extract
DrugBank: Periplaneta americana (DB10417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockroach antigen immunotherapy (CRa‐IT)
Study: 2460431
Drug: Control immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control immunotherapy (control-IT)
Study: 12396323
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg
Study: 29611504
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar placebo tablet)
Study: 23834882
Drug: Interactive educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive educational seminar on antibiotic prescription for respiratory infections
Study: 21997904
Drug: Saline irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline irrigation plus separate budesonide nasal spray (group B)
Study: 21997904
Drug: Saline irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline irrigation mixed with budesonide nasal spray (group C)
Study: 18477935
Drug: rhGH (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for > or = 15 days
Study: 16503537
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine and 20 microg/ml morphine (group L)
Study: 16503537
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine and 20 microg/ml morphine (group R)
Study: 16503537
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine and 20 microg/ml morphine (group B)
Study: 14551548
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine solution infusion catheter
Study: 14551548
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion catheter
Study: 10620552
Drug: Bicarbonate-buffered peritoneal
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-buffered peritoneal dialysis fluid (TB; 38 mmol/L of bicarbonate; pH 7.3)
Study: 10620552
Drug: Bicarbonate/lactate-buffered peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate-buffered peritoneal dialysis fluid (TBL; 25 mmol/L of bicarbonate/15 mmol/L of lactate; pH 7.3)
Study: 10620552
Drug: Acidic lactate-buffered
Normalized name: lactate / salicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic lactate-buffered peritoneal dialysis fluid (PD4; 40 mmol/L of lactate; pH 5.2)
Study: 30782886
Drug: TRAM/DKP 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAM/DKP 75/25 mg
Study: 30782886
Drug: TRAM/paracetamol 75/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAM/paracetamol 75/650 mg
Study: 28285318
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine (Group S1)
Study: 28285318
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine (Group S2)
Study: 18241321
Drug: XR‐NTX 190
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR‐NTX 190 mg
Study: 16682719
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy regimens
Study: 1349294
Drug: Infusion study
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion study in persons with mild hypothyroidism (saline or 10% dextrose)
Study: 6530305
Drug: Alteration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteration of nicotine level (specific dosage and duration not provided)
Study: 30772385
Drug: Lixisenatide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide + Basal Insulin (BI)
Study: 30772385
Drug: Sulfonylurea +
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea + Basal Insulin (BI)
Study: 28963845
Drug: Kangle Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangle Decoction at 0.5 dose bid for 8 weeks
Study: 28963845
Drug: Cialis at
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cialis at 10 mg qd alt for 8 weeks
Study: 25070961
Drug: ropinirole +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole + physical therapy
Study: 25070961
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + physical therapy
Study: 22551324
Drug: topical nipradilol
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical nipradilol
Study: 2904203
Drug: topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical timolol
Study: 22551324
Drug: topical β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical β-blocker (nipradilol or timolol)
Study: 20386073
Drug: Zidovudine 200
Normalized name: zidovudine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 200 mg
Study: 20386073
Drug: Zidovudine 300
Normalized name: zidovudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 300 mg
Study: 20386073
Drug: Amdoxovir plus
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir plus Zidovudine 200 mg
Study: 20386073
Drug: Amdoxovir plus
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir plus Zidovudine 300 mg
Study: 10099977
Drug: Low-dose step-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose step-up FSH with IUI
Study: 7380690
Drug: autologous reinfusion
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous reinfusion of approximately 900 ml of freeze-preserved blood
Study: 7380690
Drug: sham reinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham reinfusion of 50 ml of saline
Study: 30190165
Drug: 20-mg TAK-063
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg TAK-063
Study: 28284477
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei rhamnosus Lcr35 (8 × 108 colony‐forming units, n=48), twice daily for 4 weeks
Study: 28284477
Drug: Placebo (n=46),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n=46), twice daily for 4 weeks
Study: 26352940
Drug: Paracetamol mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol mixed with a liquid meal administered by a nasogastric feeding tube
Study: 26352940
Drug: Paracetamol mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol mixed with a liquid meal
Study: 26352940
Drug: Paracetamol in
Normalized name: Lloydspharmacy Paracetamol Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol in the aqueous phase of the meal
Study: 26352940
Drug: Paracetamol in
Normalized name: Lloydspharmacy Paracetamol Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol in the solid bolus of the meal
Study: 26352940
Drug: Paracetamol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol as a post prandial marker
Study: 21259004
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), with doses doubled at week 4 if LDL-C target not achieved, for 8 weeks
Study: 21259004
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), for 8 weeks
Study: 21259004
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 to 10 mg (TS 1) or 10 to 20 mg (TS ≥ 2) for 8 weeks
Study: 11443562
Drug: Intravenous palivizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palivizumab (15 mg/kg)
Study: 11443562
Drug: Intravenous palivizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palivizumab (15 mg/kg) with aerosolized ribavirin
Study: 7963081
Drug: Sugar expectancy
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar expectancy condition (mothers told their children received a large dose of sugar)
Study: 17138773
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg nightly for 4 weeks
Study: 12955028
Drug: Sex steroid
Normalized name: Sex steroid binding globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid treatment (testosterone for men, oestrogen/progestin for women)
Study: 9200306
Drug: Interferon mono-therapy
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon mono-therapy
Study: 9200306
Drug: Interferon-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin combination therapy
Study: 9200306
Drug: Prolonged interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged interferon therapy
Study: 3083211
Drug: 250 mg/d
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/d of sorbinil
Study: 27431451
Drug: Bilateral arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral arm remote ischemic postconditioning (RIPC) twice a day for 6 months
Study: 22804619
Drug: 20-G cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-G cannula
Study: 22804619
Drug: 22-G cannula
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-G cannula
Study: 21127697
Drug: Safflower seed
Normalized name: SAFFLOWER SEED
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower seed extract (SSE) 70 mg/day for 12 weeks
Study: 18492267
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedation (DIS)
Study: 10621928
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (5 mg/kg)
Study: 27179184
Drug: Treatment-as-usual PRS
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual PRS (Control)
Study: 22460438
Drug: Blastocyst group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blastocyst group (thawed and cultured in sequential media until blastocyst stage)
Study: 19687336
Drug: PLD 30
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m2 followed by docetaxel 60 mg/m2 every 21 days (n = 378)
Study: 19687336
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 (n = 373)
Study: 17578957
Drug: LMA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMA with propofol + 7.5 ng/mL remifentanil (LMA-PR)
Study: 17578957
Drug: LT with
Normalized name: Ascorbic Acid/Bioflavonoid/Biotin/Calcium/Cholecalciferol/Choline/Copper/Eleutherococcus senticosus Root/Inositol/Iodine/Iron/L-Methylfolate Glucosamine/Lutein/Magnesium/Manganese/Methylcobalamin/Molybdenum/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Rutin/Selenium/Sodium/Thiamine/Vitamin A/Vitamin E/Zinc 300 MG-20 MG-11 MCG-108.3 MG-16.7 MCG-10 MG-0.3 MG-16.7 MG-16.7 MG-50 MCG-6 MG-139.3 MCG-166.7 MCG-43.3 MG-1.93 MG-26.7 MCG-15 MCG-33.3 MG-21 MG-40 MCG-6.67 MG-6.67 MG-8.3 MG-52.67 MCG-3.33 MG-6.67 MG-900 MCG-33.3 MG-3.67 MG Oral Tablet [ALIVE! MAX3 POTENCY ADULT WITH IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT with propofol + 7.5 ng/mL remifentanil (LT-PR)
Study: 18485457
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg lornoxicam
Study: 11773166
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² plus Irinotecan 175 mg/m²
Study: 11773166
Drug: Raltitrexed 3
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 3 mg/m²
Study: 9419196
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg orally twice daily
Study: 8127329
Drug: alpha‐tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol (50 mg per day)
Study: 8127329
Drug: beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta carotene (20 mg per day)
Study: 2916913
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative physical therapy
Study: 8478756
Drug: No physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No physical therapy (Control)
Study: 791329
Drug: labetalol 400
Normalized name: labetalol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 400 mg/d
Study: 791329
Drug: labetalol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 800 mg/d
Study: 30953546
Drug: Mastery learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastery learning and deliberate practice (ML + DP)
Study: 17470884
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg x day(‐1) po, followed by 200 mg po bid for three days)
Study: 9667264
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 every 4 weeks
Study: 9667264
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly
Study: 2645420
Drug: Intracorporeal papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracorporeal papaverine (30 mg. per ml.)
Study: 2645420
Drug: Intracorporeal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracorporeal prostaglandin E1 (10 mcg. per ml.)
Study: 31043808
Drug: Generic cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Generic cetuximab ($275.80 per 100 mg)
Study: 28253845
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (MT) consisting of sleep education/restriction, psycho-education, eurythmy- and painting-therapy
Study: 28253845
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CT) consisting of multimodal therapy (MT) plus aerobic training (AT)
Study: 28253845
Drug: Standard aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aerobic treatment (AT)
Study: 26188537
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota (LcS) 6.5 × 10(9) CFU, 3 times daily for 12 weeks
Study: 26188537
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (no LcS)
Study: 10189455
Drug: Single-dose breath-hold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose breath-hold gadolinium-enhanced MR angiography with 20 mL of gadopentetate dimeglumine (average dose, 0.11 mmol/kg)
Study: 2080949
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium (9 mmol Calcium-Sandoz)
Study: 396055
Drug: Praziquantel 1
Normalized name: praziquantel 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 1 x 20 mg/kg and 2 x 20 mg/kg
Study: 28001151
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g per day of DSG for 14 days
Study: 28001151
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g per day of DSG for 30 days
Study: 28001151
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g per day of placebo for 30 days
Study: 28001151
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g per day of DSG for both studies
Study: 25648211
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones supplementation (33 g in the form of biscuits containing approximately 54 mg isoflavones for 8 weeks)
Study: 21112195
Drug: 1.4% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% gel
Study: 19679843
Drug: Endothelin-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Endothelin-receptor antagonists (ETRAs)
Study: 15329425
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg) weekly for six months
Study: 15329425
Drug: Placebo weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo weekly for six months
Study: 11336940
Drug: Unoprostone 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unoprostone 0.12% twice daily
Study: 7826846
Drug: VP‐16 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP‐16 and other drugs with leukemogenic effect in 17 patients
Study: 7826846
Drug: Only drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only drugs with leukemogenic effect in 6 patients
Study: 7826846
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs in 35 patients
Study: 30595329
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg/day
Study: 30595329
Drug: Carvedilol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (all doses combined)
Study: 22397653
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg twice daily
Study: 22397653
Drug: Pasireotide 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 900 μg twice daily
Study: 22397653
Drug: Pasireotide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (both doses)
Study: 20064692
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 1 mg ml(‐1)